People · Operator
Named in public records as an officer, director or promoter · active 2007–2025 · Other, Biotechnology, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Dataxu, Inc. | — | Other | Series B | $55.6M | $166.1M | 2007 |
| Bioscale Inc | — | Biotechnology | Series B | $44.7M | $747.7M | 2010 |
| Ekotrope, Inc. | — | Other Technology | Series A | $15.9M | $36.5M | 2016 |
| Infinite Sky Co | — | Other Technology | Seed | $1.2M | $20.4M | 2022 |
Edward Crawley at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Edward Crawley on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Kenneth Lazarus | 3 | 4 |
| Edward F. Crawley | 2 | 2 |
| Mark Johnson | 1 | 22 |
| Somu Subramaniam | 1 | 17 |
| Curtis L. Mo | 1 | 10 |
| Isaac Cheng | 1 | 9 |
| Michael Baker | 1 | 8 |
| William F. Doyle | 1 | 8 |
| Jeffrey Bussgang | 1 | 7 |
| Peter Simone | 1 | 6 |
| John Jarve | 1 | 6 |
| Mark Stein | 1 | 5 |
| Mark Jung | 1 | 5 |
| Paul Billings | 1 | 5 |
| William Doyle | 1 | 4 |
| Jeffrey Fagnan | 1 | 3 |
| BARD J. GEESAMAN | 1 | 3 |
| Bard Geesaman | 1 | 3 |
| David Rubenstein | 1 | 3 |
| Isaac S. Cheng | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.